Palmitoylethanolamide: Biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 1, 2013, Pages 4-7

  Di Marzo, Vincenzo ^a   Skaper, Stephen D ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ENDOCANNABINOID; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLETHANOLAMINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; DEGENERATIVE DISEASE; EDITORIAL; GLIA CELL; MASS SPECTROMETRY; MAST CELL; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; TISSUE INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENDOCANNABINOIDS; ETHANOLAMINES; GENETIC PLEIOTROPY; HUMANS; LIPID METABOLISM; NERVOUS SYSTEM DISEASES; PALMITIC ACIDS;

EID: 84875287387     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312010004     Document Type: Editorial

References (13)

1. Suk, K.; Ock, J. Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors. Inflammopharmacology, 2011, 20, 151-158.
2. Petrosino, S.; Iuvone, T.; Di Marzo, V. N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie., 2010, 92, 724-727.
3. Coburn, A.F.; Moore, L.V. Nutrition as conditioning factor in the rheumatic state. Am. J. Dis. Child., 1943, 65, 744-756.
4. Coburn, A.F.; Graham, C.E.; Hahinger, J. Effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J. Exp. Med., 1954, 100, 425-435.
5. Kuehl, F.A.; Jacob, T.A.; Ganley, O.H.; Ormond, R.E; Meisinger, M.A.P. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc., 1957, 79, 5577-5578.
6. Mazzari, S.; Canella, R.; Petrelli, L., Marcolongo, G; Leon, A.N (2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by downmodulating mast cell activation. Eur. J. Pharmacol, 1996, 300, 227-236.
7. Calignano, A.; La Rana, G.; Giuffrida, A; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature, 1998, 394, 277-281.
8. Lambert, D.M.; Vandevoorde, S.; Diependaele, G., Govaerts, S.J; Robert, A.R. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia, 2001, 42, 321-327.
9. Sheerin, A.H.; Zhang, X.; Saucier, D.M.; Corcoran, M.E. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia, 2004, 45, 1184-1188.
10. Truini, A.; Biasiotta, A.; Di Stefano, G.; La Cesa, S.; Leone, C; Cartoni, C; Federico, V.; Petrucci M.; Cruccu G. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol. Disord. Drug Targets, 2011, 10, 916-920.
11. Kopsky, D.J.; Hesselink, J.M. Multimodal stepped care approach with acupuncture and PPAR-a agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct. Med., 2012, 30, 53-55.
12. Hesselink, J.M.K. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. The Open Pain Journal, 2012, 5, 12-23.
13. Clemente, S. Amytrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: A case report. CNS Neurol. Disord. Drug Targets, 2012, 11, 933-936.